Drug Approval | October 02, 2024
SMS Pharma receives EDQM certification to supply Ibuprofen in Europe
The inspection conducted by EDQM at its Visakhapatnam facility
The inspection conducted by EDQM at its Visakhapatnam facility
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
